- 英文名称
- Resmetirom
- 分子式
- C17H12Cl2N6O4
- 分子量
- 435.22
- 中文别名
- 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈; MGL-3196; 瑞斯美罗; MGL-3196游离态; 化合物MGL3196; 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧基-2,3,4,5-四氢-1,2,4-三嗪-6-碳腈; 2-[3,5-二氯-4-[(5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基]苯基]-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-甲腈; 瑞森泰罗; 瑞斯美替尼; 2-(3,5-Dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile; 1,2,4-Triazine-6-carbonitrile, 2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo; 2-[3,5-Dichloro-4-[(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy]phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine-6-carbonitrile; MGL 3196; MGL3196; VIA-3196; VIA3196; 2-[3,5-Dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile
- 用途
- 化学合成;MASH靶向药物,是全球首个获批用于治疗伴有中晚期肝纤维化(F2-F3期)的非肝硬化MASH患者的药物;甲状腺激素受体-β(THR-β)的部分激动剂,对THR-β的选择性是THR-α的28倍,EC50为0.21μM;肝定向、口服活性、选择性的thyroid hormone receptor β(THR-β)激动剂;主要副作用为腹泻与恶心,安全性良好